Literature DB >> 10623811

Resting B lymphocytes as APC for naive T lymphocytes: dependence on CD40 ligand/CD40.

D E Evans1, M W Munks, J M Purkerson, D C Parker.   

Abstract

Although resting B cells as APC are tolerogenic for naive T cells in vivo, we show here that they can provide all the costimulatory signals necessary for naive T cell proliferation in vivo and in vitro. In the absence of an activating signal through the B cell Ag receptor, T cell proliferation after Ag recognition on resting B cells depends on CD40 expression on the B cells, implying that naive T cells use the membrane-bound cytokine, CD40 ligand (CD154), to induce the costimulatory signals that they need. Induction of B7-1 (CD80) and increased or sustained expression of CD44H, ICAM-1 (CD54), and B7-2 (CD86) are dependent on the interaction of CD40 ligand with CD40. Transient expression (12 h) of B7-2 is T cell- and peptide Ag-dependent, but CD40-independent. Only sustained (>/=24 h) expression of B7-2 and perhaps increased expression of ICAM-1 could be shown to be functionally important in this system. T cells cultured with CD40-deficient B cells and peptide remain about as responsive as fresh naive cells upon secondary culture with whole splenic APC. Therefore, B cells, and perhaps other APC, may be tolerogenic not because they fail to provide sufficient costimulation for T cell proliferation, but because they are deficient in some later functions necessary for a productive T cell response.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623811     DOI: 10.4049/jimmunol.164.2.688

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation.

Authors:  L Coscoy; D Ganem
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

2.  Presentation of high antigen-dose by splenic B220(lo) B cells fosters a feedback loop between T helper type 2 memory and antibody isotype switching.

Authors:  Jason S Ellis; F Betul Guloglu; Habib Zaghouani
Journal:  Immunology       Date:  2016-01-28       Impact factor: 7.397

3.  A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells.

Authors:  Melissa Santone; Susanna Aprea; Tom Y H Wu; Michael P Cooke; M Lamine Mbow; Nicholas M Valiante; James S Rush; Stephanie Dougan; Ana Avalos; Hidde Ploegh; Ennio De Gregorio; Cecilia Buonsanti; Ugo D'Oro
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Presentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naive B cells.

Authors:  Wei Jiang; Michael M Lederman; Clifford V Harding; Scott F Sieg
Journal:  J Immunol       Date:  2011-01-14       Impact factor: 5.422

5.  Expression of activated molecules on CD5(+)B lymphocytes in autoimmune hemolytic anemia.

Authors:  Hongli Zhu; Wenyan Xu; Hong Liu; Huaquan Wang; Rong Fu; Yuhong Wu; Wen Qu; Guojin Wang; Jing Guan; Jia Song; Limin Xing; Zonghong Shao
Journal:  Int J Hematol       Date:  2016-03-11       Impact factor: 2.490

6.  B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma.

Authors:  Marianela Candolfi; James F Curtin; Kader Yagiz; Hikmat Assi; Mia K Wibowo; Gabrielle E Alzadeh; David Foulad; A K M G Muhammad; Sofia Salehi; Naomi Keech; Mariana Puntel; Chunyan Liu; Nicholas R Sanderson; Kurt M Kroeger; Robert Dunn; Gislaine Martins; Pedro R Lowenstein; Maria G Castro
Journal:  Neoplasia       Date:  2011-10       Impact factor: 5.715

7.  Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1.

Authors:  Chuanlin Ding; Li Wang; Jose Marroquin; Jun Yan
Journal:  Blood       Date:  2008-07-31       Impact factor: 22.113

8.  T cell immunity using transgenic B lymphocytes.

Authors:  Mara Gerloni; Marta Rizzi; Paola Castiglioni; Maurizio Zanetti
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-02       Impact factor: 11.205

9.  B cell infection and activation by rabies virus-based vaccines.

Authors:  Andrew G Lytle; James E Norton; Corin L Dorfmeier; Shixue Shen; James P McGettigan
Journal:  J Virol       Date:  2013-06-12       Impact factor: 5.103

10.  Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen.

Authors:  S Guo; J Xu; W Denning; Z Hel
Journal:  Gene Ther       Date:  2009-07-30       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.